All News

Here at Drug Channels, we’ve been closely tracking the evolution of the pharmacy benefit management (PBM) indu…

It's part of Democrats' strategy to focus on health care affordability and access in drawing contrasts with Re…

Already tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early brea…

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on…

The average Affordable Care Act (ACA) Marketplace deductible experienced the steepest increase in history—grow…

With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknow…

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli…

Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, markin…

With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be head…

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA…

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been app…

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early b…

A number of Americans who are in the Congo are believed to have had exposure to suspected cases in the country…

With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator is heading …

Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in ab…

The U.S. Supreme Court has issued an emergency order, temporarily blocking a federal appeals court ruling in L…

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But …

The leader of the FDA's drug division, Tracy Beth Høeg, is expected to depart, as part of a broad shakeup at t…

Biopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withst…

Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal dru…